UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
Financial Post · · g2988507
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44 Duvakitug was well tolerated and safety was consistent with the induction study PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) […]
PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013 ) in patients with moderately-to-severely active ulcerative colitis (UC) or Crohn’s disease (CD), which demonstrated that duvakitug maintained clinically meaningful efficacy improvements across multiple endpoints over 44 weeks. Duvakitug is an investigational human monoclonal antibody that targets TL1A, a protein that amplifies inflammation and potentially drives fibrosis in UC and CD. Read More